Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dociparstat in newly diagnosed AML
NCT04571645Phase 3Terminated
- Sponsor
- Chimerix Inc.
- Start
- Apr 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) (2 arms), sponsored by Chimerix Inc. Primary endpoint: Overall Survival at 1 year. Started Apr 2021; status: terminated.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04571645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571645.